Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts

Cardiovascular Research

Volumn 82, Issue 3, 2009, Pages 542-549

  Reisinger, Ute ^a   Schwaiger, Stefan ^b   Zeller, Iris ^a   Messner, Barbara ^a   Stigler, Robert ^a   Wiedemann, Dominik ^a   Mayr, Tobias ^a   Seger, Christoph ^a   Schachner, Thomas ^a   Dirsch, Verena M ^c   Vollmar, Angelika M ^d   Bonatti, Johannes O ^a   Stuppner, Hermann ^b   Laufer, Günther ^a   Bernhard, David ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Intimal hyperplasia; Lignan; Neointima; Therapy

Indexed keywords

LEOLIGIN; LIGNAN DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ASTERACEAE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; GRAFT DYSFUNCTION; HUMAN; HUMAN CELL; LEONTOPODIUM ALPINUM; MALE; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; THROMBOCYTE FUNCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ASTERACEAE; BLOOD PLATELETS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIAL CELLS; G1 PHASE; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; LIGNANS; MICE; MYOCYTES, SMOOTH MUSCLE; PHYTOTHERAPY; PLANT EXTRACTS; SAPHENOUS VEIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 66249125700     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp059     Document Type: Article

References (34)

1. WHO. Cardiovascular diseases. 2007.
2. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg 2004;77:93-101.
3. Schachner T, Laufer G, Bonatti H. The role of vein grafts in coronary surgery. European Surgery 2007;39:72-75.
4. Lau GT, Lowe HC, Kritharides L Cardiac saphenous vein bypass graft disease. Semin Vasc Med 2004;4:153-159.
5. Tsui JC, Dashwood MR. Recent strategies to reduce vein graft occlusion: a need to limit the effect of vascular damage. Eur J Vasc Endovasc Surg 2002;23:202-208.
6. Hozumi T, Yoshikawa J, Yoshida K, Akasaka T, Takagi T, Honda Y et al. Use of intravascular ultrasound for in vivo assessment of changes in intimal thickness of angiographically normal saphenous vein grafts one year after aortocoronary bypass surgery. Heart 1996;76:317-320.
7. Marin ML, Veith FJ, Panetta TF, Gordon RE, Wengerter KR, Suggs WD et al. Saphenous vein biopsy: a predictor of vein graft failure. J Vasc Surg 1993;18:407-414.
8. Lau GT, Ridley LJ, Bannon PG, Wong LA, Trieu J, Brieger DB et al. Lumen loss in the first year in saphenous vein grafts is predominantly a result of negative remodeling of the whole vessel rather than a result of changes in wall thickness.Circulation 2006;114:I435-I440.
9. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunologi-cal mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006;84:115-124.
10. Schmieder A, Schwaiger S, Csordas A, Backovic A, Messner B, Wick G et al. Isogentisin - a novel compound for the prevention of smoking-caused endo-thelial injury. Atherosclerosis 2007;194:317-325.
11. Dobner MJ, Ellmerer EP, Schwaiger S, Narantuya S, Ododnchimeg B, Stütz M et al. New lignan, benzofuran and sesquiterpen derivatives from the roots of Leontopodium alpinum and L leontopodioides. Helvetica Chimica Acta 2003;86:2284-2285.
12. Bernhard D, Pfister G, Huck CW, Kind M, Salvenmoser W, Bonn GK et al. Disruption of vascular endothelial homeostasis by tobacco smoke: impact on atherosclerosis. FASEB J 2003;17:2302-2304.
13. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 1979;59:1-61.
14. Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 1999;13: 1991-2001.
15. Grabner R, Till U, Heller R. Flow cytometric determination of E-selectin, vascular cell adhesion molecule-1, and intercellular cell adhesion molecule-1 in formaldehyde-fixed endothelial cell monolayers. Cytome-try 2000;40:238-244.
16. Bernhard D, Skvortsov S, Tinhofer I, Hubl H, Greil R, Csordas A et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ 2001 ;8:1014-1021.
17. Schachner T, Laufer G, Bonatti J. In vivo (animal) models of vein graft disease. Eur J Cardiothorac Surg 2006;30:451-463.
18. Schachner T, Heiss S, Zipponi D, Tzankov A, Bernecker O, Kroell A et al. Perivascular treatment with azathioprine reduces neointimal hyperplasia in experimental vein grafts. Heart Surg Forum 2006;9:E515-E517.
19. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-415.
20. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163.
21. Keiss HP, Schwaiger S, Dobner MJ, Stuppner H, Vollmar AM, Dirsch VM. A lignan from Leontopodium alpinum inhibits the TNF-a-induced expression of ICAM-1 and E-Selectin in a NF-kappaB-independent manner. Naunyn Schmiedebergs Arch Pharmacol 2002;687(Suppl. 1) (Abstract).
22. Schwaiger S, Adams M, Seger C, Ellmerer EP, Bauer R, Stuppner H. New constituents of Leontopodium alpinum and their in vitro leukotriene biosynthesis inhibitory activity. Planta Med 2004;70:978-985.
23. Kim Y, Kim SB, You YJ, Ahn BZ. Deoxypodophyllotoxin;the cytotoxic and antiangiogenic component from Pulsatilla koreana. Planta Med 2002;68: 271-274.
24. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, Lee WS. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 2002;84: 532-544.
25. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B et al. Honokiol, a small molecular weight natural product, inhibits angio-genesis in vitro and tumor growth in vivo. J Biol Chem 2003;278: 35501-35507.
26. Bergman JM, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007;13:1061-1067.
27. Zhang X, Chen S, Wang Y. Honokiol up-regulates prostacyclin synthease protein expression and inhibits endothelial cell apoptosis. Eur J Pharmacol 2007;554:1-7.
28. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 2006;4:621-633.
29. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-mediated G(1 )-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett 2006;580:5177-5184.
30. Chen JH, Wu CC, Hsiao G, Yen MH. Magnolol induces apoptosis in vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2003;368: 127-133.
31. Chen YH, Lin SJ, Chen JW, Ku HH, Chen YL. Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits. Br J Pharmacol 2002;135:37-47.
32. Chen SC, Chang YL, Wang DL, Cheng JJ. Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br J Pharmacol 2006;148:226-232.
33. Razuvaev A, Henderson B, Girnita L, Larsson O, Axelson M, Hedin U et al. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg 2007;46:108-115.
34. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.Nat Med 2002;8:1249-1256.